We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

81 hedge funds and large institutions have $361M invested in Iovance Biotherapeutics in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

759% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $139K

24% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 25

5% more capital invested

Capital invested by funds: $345M → $361M (+$16.1M)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7% less funds holding

Funds holding: 87 → 81 (-6)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
81
Holders Change
-6
Holders Change %
-6.9%
% of All Funds
2.02%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
5
Increased
31
Reduced
25
Closed
6
Calls
$1.19M
Puts
$139K
Net Calls
+$1.05M
Net Calls Change
+$2.02M

Top Buyers

1
BlackRock
BlackRock
New York
+$44.5M
2
GTC
Ghost Tree Capital
New York
+$1.65M
3
Goldman Sachs
Goldman Sachs
New York
+$1.45M
4
Victory Capital Management
Victory Capital Management
Texas
+$1.45M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.04M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.62M
2
ACP
Acuta Capital Partners
California
-$2.89M
3
SM
Sabby Management
Florida
-$1.22M
4
First Eagle Investment Management
First Eagle Investment Management
New York
-$1.04M
5
UBS Group
UBS Group
Switzerland
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$828K -$36.6K -5,000 -4%
TA
27
Teachers Advisors
New York
$648K +$26.2K +3,572 +4%
Morgan Stanley
28
Morgan Stanley
New York
$624K -$681K -92,925 -53%
Swiss National Bank
29
Swiss National Bank
Switzerland
$556K – – –
CG
30
Cutler Group
California
$482K +$327K +44,629 +222%
SM
31
Sabby Management
Florida
$448K -$1.22M -165,925 -73%
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$437K +$17.7K +2,421 +4%
Citadel Advisors
33
Citadel Advisors
Florida
$399K +$93.9K +12,806 +31%
OPPM
34
Opus Point Partners Management
New York
$396K +$104K +14,210 +36%
Russell Investments Group
35
Russell Investments Group
United Kingdom
$386K +$379K +51,761 New
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$380K +$7 +1 +0%
Wells Fargo
37
Wells Fargo
California
$374K +$88K +12,000 +31%
Manulife (Manufacturers Life Insurance)
38
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$334K +$45.5K +6,212 +16%
CIBC Private Wealth Group
39
CIBC Private Wealth Group
Georgia
$320K – – –
OAM
40
Oxford Asset Management
United Kingdom
$297K -$442K -60,256 -60%
PCM
41
Prelude Capital Management
New York
$297K +$111K +15,116 +61%
ProShare Advisors
42
ProShare Advisors
Maryland
$296K -$76.1K -10,386 -21%
AllianceBernstein
43
AllianceBernstein
Tennessee
$295K – – –
VEA
44
Virtus ETF Advisers
New York
$294K +$27.7K +3,779 +11%
MLICM
45
Metropolitan Life Insurance Company (MetLife)
New York
$278K – – –
CS
46
Credit Suisse
Switzerland
$265K +$9.9K +1,351 +4%
AIG
47
American International Group
New York
$255K +$58.7K +8,007 +31%
NFA
48
Nationwide Fund Advisors
Ohio
$239K -$17.4K -2,373 -7%
LCM
49
Landscape Capital Management
New Jersey
$239K +$94K +12,831 +67%
TI
50
Trexquant Investment
Connecticut
$197K +$194K +26,449 New
1
2
3 4

IOVA Hedge Fund Activity: Q1 2017 in Review

81 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2017, worth a combined $361M — up 4.7% from $345M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IOVA and 5 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.

The largest buyer was BlackRock, adding an estimated $44.5M. The largest seller was Fidelity Investments, cutting an estimated $4.62M.

  • 81 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2017, down from 87 in Q4 2016.
  • Funds reported $361M of Iovance Biotherapeutics stock for Q1 2017, up 4.7% quarter-over-quarter.
  • 5 funds opened new Iovance Biotherapeutics positions in Q1 2017 and 6 closed out, a net change of -1 holder.
  • The largest Iovance Biotherapeutics buyer in Q1 2017 was BlackRock, an estimated $44.5M added.
  • The largest Iovance Biotherapeutics seller in Q1 2017 was Fidelity Investments, an estimated $4.62M sold.

Based on aggregated 13F filings for Q1 2017.